Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Anna Schuh awarded funding from the NIHR RIGHT programme

4 November 2019

The NIHR has invested £34 million of funding into global health research projects to tackle epilepsy, infection-related cancers and severe stigmatising skin diseases in low- and middle-income countries (LMICs).

The NIHR Research and Innovation for Global Health Transformation (RIGHT) programme has awarded Official Development Assistance (ODA) funding to eight projects led by teams made up of researchers in the UK and those in LMICs.

Professor Anna Schuh from the Department of Oncology is leading one of the eight projects, and will be investigating two new techniques to diagnose Epstein-Barr virus, a common cause of blood cancers in sub-Saharan Africa. Her research in Tanzania and Uganda aims to speed up diagnosis and treatment of the infection, reducing the mortality rate from these cancers.

For more information on the full recipients of funding for this programme grant, please go to https://www.nihr.ac.uk/news/nihr-invests-34-million-into-global-health-research-on-epilepsy-infection-related-cancers-and-severe-stigmatising-skin-diseases/22764

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.